The scientific advances reported at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, were extraordinary. This years meeting saw first-time attempts at integrating multiple levels of biological data analysis, including genomics, epigenetics and immunological profiling, which were exciting from both a biological and clinical standpoint. Speaking from the meeting, Kenneth Anderson, MD, of the Dana-Farber Cancer Institute, Boston, MA, and 2017 ASH President, gives his top picks of the most exciting areas of hemonc to look out for over the coming year.
The future is bright for hematological oncology: promising areas for 2018 and beyond
